ArticleAmerican journal of hematology2017

Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias.

Brittany Knick Ragon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.